Name: Cereno’s CEO on being granted “Compassionate Use”
Uploaded: 2024-02-06T08:45:22+01:00
Channel: Michael Jewett
Description: Cereno Scientific has been granted Expanded Access by the FDA for drug candidate CS1 in rare disease pulmonary arterial hypertension.

Cereno’s CEO on being granted “Compassionate Use”

6 February, 2024

Cereno listed on Nasdaq First North Growth Market

15 June, 2023

Tag: cereno cardiovascular disease

Cereno’s CEO on being granted “Compassionate Use”

Cereno listed on Nasdaq First North Growth Market